Does azithromycin-prednisolone combination therapy have additive effects than single therapy in patients with persistent asthma? Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009
Long-term oral corticosteroid-sparing effects of anti-IL5/anti-IL5 receptor treatment. Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021
Early treatment response may predict long-term mepolizumab benefit in severe asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019
Immunomodulatory treatment of severe persistent asthma with interferon-αcon-1 (IFN-αcon-1). Effect on the clinical course of oral corticosteroid dose and eosinophil numbers Source: Annual Congress 2003 - Modulation of bronchial hyperreactivity and immune response in the airways Year: 2003
Fluticasone/salmeterol combination (FSC) is safe and provides effective long-term (52 week) control in the management of patients with persistent asthma (PA) Source: Eur Respir J 2001; 18: Suppl. 33, 176s Year: 2001
Using remote directly observed therapy (R-DOT) for optimising asthma therapy. Source: International Congress 2017 – Small airways, long distances and large databases in paediatric asthma Year: 2017
Evaluation of prophylactic observations efficacy and the quality of TB treatment using a math model for primarily revealed patients Source: Eur Respir J 2004; 24: Suppl. 48, 722s Year: 2004
Adjustable maintenance dosing with budesonide/formoterol provides effective asthma symptom control at a lower average dose than fixed dosing: results of a study in Italy Source: Eur Respir J 2003; 22: Suppl. 45, 411s Year: 2003
Combination therapy with sotatercept analog RAP-011 is superior to sildenafil alone in severe experimental PAH and RAP-011 benefits persist after treatment cessation Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension Year: 2020
Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 5s Year: 2001
Optimum dosing regimen for repeated low dose allergen challenge in chronic allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 103s Year: 2001
An inhaled “bifunctional” dual PDE3/4 inhibitor provides additional short-term improvements in lung function compared to existing classes of bronchodilator: implications for future treatment of COPD Source: Eur Respir J, 52 (5) 1801675; 10.1183/13993003.01675-2018 Year: 2018
Long-term treatment with fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy is well-tolerated and provides sustained effectiveness in paediatric patients with asthma Source: Annual Congress 2011 - Treating childhood asthma Year: 2011
Adjustable maintenance dosing with budesonide/formoterol controls asthma symptom severity and maintains lung function with a lower overall dose than fixed dosing: results of an Italian study Source: Eur Respir J 2003; 22: Suppl. 45, 259s Year: 2003
Comparable efficacy of calcilytic and corticosteroid in short-term and long-term allergic asthma models in vivo Source: International Congress 2018 – Determinants and monitoring of asthma control Year: 2018
Evaluation of efficacy and safety of budesonide/formeterol combination therapy in asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 314s Year: 2006
Is there a benefit of an additive standard immunoglobulin therapy for the clinical course of COPD patients under chronic immunosuppressive therapy? Source: Eur Respir J 2001; 18: Suppl. 33, 24s Year: 2001
Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007
COPD exacerbation: resolution of symptoms after starting antibiotic treatment was unaltered by the timing of therapy but was dependent on baseline gas transfer Source: Annual Congress 2008 - Management of COPD Year: 2008